We identified several kinase inhibitors targeting the PI3K/AKT, MAPK, and JAK pathways, as well as pan-tyrosine kinase inhibitors, that uniformly inhibited the growth of T-ALL cells. Here, AKT1 is linked to acute lymphoblastic leukemia.